Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1
Beth I Solomon, Andrew C Smith, Ninet Sinaii, Nicole Farhat, Monique C King, Leonza Machielse, Forbes D Porter, Beth I Solomon, Andrew C Smith, Ninet Sinaii, Nicole Farhat, Monique C King, Leonza Machielse, Forbes D Porter
Abstract
Importance: Niemann-Pick disease, type C1 (NPC1) is a progressive neurovisceral disease with no US Food and Drug Administration-approved therapy. Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression. Several prospective trials suggest that miglustat stabilizes oropharyngeal swallowing function; however, its effect on dysphagia and aspiration risk has not been demonstrated instrumentally.
Objective: To determine if miglustat therapy is associated with stabilized swallowing dysfunction in individuals with NPC1.
Design, setting, and participants: Patients with confirmed NPC1 diagnoses were evaluated in a single-center cohort study of NPC1 from April 1997 to November 2019. Longitudinal data from individuals with neurologic disease onset prior to age 15 years were analyzed. The study population was divided into those with neurologic disease onset in early childhood (age <6 years) and late childhood (age ≥6 years and <15 years). Analysis began September 2019.
Exposures: Oral miglustat at baseline and at follow-up.
Main outcomes and measures: Oropharyngeal swallowing function was assessed with videofluoroscopic swallowing studies. Overall swallowing ability and aspiration risk were evaluated using the American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain and an adapted Rosenbek aspiration-penetration scale, respectively.
Results: Overall, 50 participants were evaluated at baseline (median [interquartile range] age, 9.4 [3.4-16.4] years; 26 [52%] female). The median (interquartile range) duration of follow-up was 3.0 (1.1-4.4) years. Miglustat use was associated with decreased odds of worse American Speech-Language-Hearing Association National Outcome Measurement System swallowing domain outcomes in all 3 subsets (overall: odds ratio [OR], 0.09 [95% CI, 0.02-0.36); P < .001; early childhood: OR, 0.17 [95% CI, 0.04-0.67]; P = .01; late childhood: OR, 0.05 [95% CI, 0.01-0.29]; P = .001). Miglustat use was associated with decreased odds of worse Rosenbek aspiration-penetration scale outcomes in the overall cohort (OR, 0.28 [95% CI, 0.08-0.95]; P = .04) but not in each subgroup (early childhood: OR, 0.27 [95% CI, 0.06-1.22]; P = .09; late childhood: OR, 0.38 [95% CI, 0.06-2.33]; P = .29).
Conclusions and relevance: These data suggest that miglustat use is associated with stabilized swallowing function and reduced aspiration risk in NPC1, thus supporting its use in this population. In addition, these data demonstrate that a quantification of swallowing dysfunction can be used as a clinically relevant, functional outcome measure in future therapeutic trials in NPC1.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Porter reports grants from National Institutes of Health and Ara Parseghian Medical Research Foundation during the conduct of the study; grants from National Institutes of Health, Ara Parseghian Medical Research Foundation, Together Strong NPC Foundation, and Firefly Fund outside the submitted work; other support from Mallinckrodt, Amicus Therapeutics, and UltraGenix outside the submitted work; and has patents on Niemann-Pick disease, type C biomarkers issued. No other disclosures were reported.
Figures
![Figure 1.. Predicted Cumulative Probabilities of Disease…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7489403/bin/jamaneurol-e203241-g001.jpg)
Figure 2.. Association of Miglustat Use With…
Figure 2.. Association of Miglustat Use With Overall Ability to Eat and Swallow Safely and…
- Characterization of Dysphagia and Longitudinal Changes in Swallowing Function in Adults with Niemann-Pick Disease Type C Treated with Miglustat.Lewis C, Keage M, Watanabe M, Schubiger D, Velakoulis D, Walterfang M, Vogel AP. Lewis C, et al. Dysphagia. 2021 Jun;36(3):362-373. doi: 10.1007/s00455-020-10145-8. Epub 2020 Jun 19. Dysphagia. 2021. PMID: 32562141
- The videofluoroscopic swallowing study shows a sustained improvement of dysphagia in children with Niemann-Pick disease type C after therapy with miglustat.Fecarotta S, Amitrano M, Romano A, Della Casa R, Bruschini D, Astarita L, Parenti G, Andria G. Fecarotta S, et al. Am J Med Genet A. 2011 Mar;155A(3):540-7. doi: 10.1002/ajmg.a.33847. Epub 2011 Feb 22. Am J Med Genet A. 2011. PMID: 21344635
- Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.Héron B, Valayannopoulos V, Baruteau J, Chabrol B, Ogier H, Latour P, Dobbelaere D, Eyer D, Labarthe F, Maurey H, Cuisset JM, de Villemeur TB, Sedel F, Vanier MT. Héron B, et al. Orphanet J Rare Dis. 2012 Jun 7;7:36. doi: 10.1186/1750-1172-7-36. Orphanet J Rare Dis. 2012. PMID: 22676771 Free PMC article. Clinical Trial.
- Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study.Patterson MC, Mengel E, Vanier MT, Schwierin B, Muller A, Cornelisse P, Pineda M; NPC Registry investigators. Patterson MC, et al. Orphanet J Rare Dis. 2015 May 28;10:65. doi: 10.1186/s13023-015-0284-z. Orphanet J Rare Dis. 2015. PMID: 26017010 Free PMC article.
- Miglustat in Niemann-Pick disease type C patients: a review.Pineda M, Walterfang M, Patterson MC. Pineda M, et al. Orphanet J Rare Dis. 2018 Aug 15;13(1):140. doi: 10.1186/s13023-018-0844-0. Orphanet J Rare Dis. 2018. PMID: 30111334 Free PMC article. Review.
- Alterations in Cholesterol and Phosphoinositides Levels in the Intracellular Cholesterol Trafficking Disorder NPC.Cologna SM, Pathmasiri KC, Pergande MR, Rosenhouse-Dantsker A. Cologna SM, et al. Adv Exp Med Biol. 2023;1422:143-165. doi: 10.1007/978-3-031-21547-6_5. Adv Exp Med Biol. 2023. PMID: 36988880
- Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1.Campbell K, Cawley NX, Luke R, Scott KEJ, Johnson N, Farhat NY, Alexander D, Wassif CA, Li W, Cologna SM, Berry-Kravis E, Do AD, Dale RK, Porter FD. Campbell K, et al. Biomark Res. 2023 Jan 31;11(1):14. doi: 10.1186/s40364-023-00448-x. Biomark Res. 2023. PMID: 36721240 Free PMC article.
- Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.Agrawal N, Farhat NY, Sinaii N, Do AD, Xiao C, Berry-Kravis E, Bianconi S, Masvekar R, Bielekova B, Solomon B, Porter FD. Agrawal N, et al. Genet Med. 2023 Mar;25(3):100349. doi: 10.1016/j.gim.2022.11.017. Epub 2022 Dec 5. Genet Med. 2023. PMID: 36470574
- Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.Gutić M, Milosavljević MN, Janković SM. Gutić M, et al. Int J Clin Pharm. 2022 Dec;44(6):1442-1453. doi: 10.1007/s11096-022-01491-8. Epub 2022 Oct 15. Int J Clin Pharm. 2022. PMID: 36243834
- Phenotypic expression of swallowing function in Niemann-Pick disease type C1.Solomon BI, Muñoz AM, Sinaii N, Farhat NM, Smith AC, Bianconi S, Dang Do A, Backman MC, Machielse L, Porter FD. Solomon BI, et al. Orphanet J Rare Dis. 2022 Sep 5;17(1):342. doi: 10.1186/s13023-022-02472-w. Orphanet J Rare Dis. 2022. PMID: 36064725 Free PMC article.
- Research Support, N.I.H., Intramural
- 1-Deoxynojirimycin / analogs & derivatives*
- 1-Deoxynojirimycin / therapeutic use
- Adolescent
- Child
- Child, Preschool
- Cohort Studies
- Deglutition / drug effects*
- Deglutition Disorders / etiology
- Enzyme Inhibitors / therapeutic use*
- Female
- Humans
- Male
- Niemann-Pick Disease, Type C / complications*
- Niemann-Pick Disease, Type C / drug therapy*
- Pneumonia, Aspiration / etiology
- Pneumonia, Aspiration / prevention & control
- Enzyme Inhibitors
- 1-Deoxynojirimycin
- miglustat
- Full Text Sources
- Medical
- Miscellaneous
![Figure 2.. Association of Miglustat Use With…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7489403/bin/jamaneurol-e203241-g002.jpg)
Source: PubMed